Seminar: Identifying diagnostic and therapeutic targets in MALT lymphoma and breast cancer using whole transcriptome NGS

SIMR-Meeting Room (M-32) 15 FEB 20173 PM

Identifying diagnostic and therapeutic targets in MALT lymphoma and breast cancer using whole transcriptome NGS

Dr. Rifat Hamoudi, PhD, Recently Joined SIMR-College of Medicine and hold the position of associate professor in Bioinformatics/OMICS.

Former Address: University College London-UK

Many NGS projects have focused on mutational profiling using DNA sequencing. However, because of intra-tumoral heterogeneity, multi-omics platform are needed to provide deeper insights into the molecular mechanism of MALT lymphoma and breast cancer.

This seminar will discuss the problems in applying transcriptomics to clinical biopsies and the limitation in transcriptome bioinformatics analysis and how to overcome those using novel molecular and computational pathology methods. The seminar will use real data obtained from a study to decipher the molecular mechanism of MALT lymphoma identifying differential diagnostic biomarkers and therapeutic targets in the process. Also the seminar will discuss a more recent study to identify diagnostic biomarkers in various stages of breast cancer using FFPE clinical biopsies. Finally, a collaborative pharmacogenomics study using HDAC inhibitors will be introduced as another way to characterise the mechanism of drug action and identify the potential mechanisms behind multidrug resistance.​


Dr. Rifat Hamoudi, PhD, Chartered Scientist and Chartered Engineer is a multidisciplinary researcher. He started out as electronic engineer but moved into medical sciences. He has BSc in Biology and Chemistry, Three different MSc degrees from University of London in Engineering, Computer Science and Biochemistry and a PhD from Cambridge University in Molecular Medicine and Pathology.

He worked in cancer genetics at the Royal Marsden Hospital and Institute of Cancer Research and was a member of the team that discovered BRCA2. Following the publishing of the human genome in 2001 he moved to work in molecular pathology establishing and applying novel wet methodologies, algorithms and software for molecular screening and personalised medicine, diagnostic and prognostic biomarker discoveries and understanding the molecular mechanism of various diseases with a view to identifying key therapeutic targets. More recently, he has used therapeutic targets in photo and photo and sono-dynamic therapy to address the problems of heterogeneity and clonal evolution in disease.

He has co-initiated the Personal Genome Project - UK with Professor Stephan Beck and is the lead in software and algorithms development and has written many information management system software using various software engineering methodologies to collate, store clinico-pathology information and correlate that to genomics data.





Back to list